Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Condition:   Plaque Psoriasis Interventions:   Drug: Humira (Adalimumab);   Drug: SB5 (Adalimumab Biosimilar) Sponsor:   Samsung Bioepis Co., Ltd. Recruiting

Source: ClinicalTrials.gov - August 22, 2022 Category: Research Source Type: clinical trials